Orris

Acute onset SOB with dilated RA with severe TR with moderate PAH evaluation management +and treatment

Reading File
Finding Sources
Finding Sources
Searching PubMed

"tricuspid valve insufficiency" AND management

Searching the Web

2022 ESC ERS pulmonary hypertension guidelines diagnostic algorithm right heart catheterization tricuspid regurgitation

Finding Sources
Finding Sources
Searching PubMed

"pulmonary hypertension" AND "right heart failure"

Reading File
Reading File
Reading Web Page

https://erj.ersjournals.com/content/early/2022/08/25/1399300…

Finding Sources
Acute dyspnea with a dilated right atrium (RA), severe tricuspid regurgitation (TR), and apparent moderate pulmonary hypertension (PH) requires urgent hospital-based evaluation. Do not assume PH is the primary cause from echocardiography alone. Severe TR can make Doppler-estimated pulmonary artery pressure unreliable, and abrupt symptoms raise concern for pulmonary embolism, acute RV failure, acute worsening of chronic TR, arrhythmia, acute left-heart disease, or infective endocarditis.

1. Immediate assessment and stabilization

Treat as an acute cardiopulmonary presentation:
  • ABCs, continuous cardiac monitoring, two IV lines
  • Oxygen only if hypoxemic, aiming to correct hypoxia without routine excess oxygen
  • Record BP, HR, RR, temperature, mental status, urine output, JVP, peripheral edema/ascites, hepatomegaly
  • Assess for shock or RV failure: hypotension, cool extremities, rising lactate, oliguria, confusion
  • ECG, bedside chest radiograph, ABG/VBG with lactate if unwell
  • Blood tests: CBC, renal function/electrolytes, liver profile and INR, troponin, BNP/NT-proBNP, CRP, thyroid tests
  • Blood cultures before antibiotics if fever, septic features, IV drug use, indwelling line, embolic phenomena, or a valve vegetation is suspected
Escalate immediately to ICU/cardiology/PH specialist if hypotension, syncope, hypoxemia, rising lactate, severe RV dysfunction, altered mentation, or suspected high-risk PE.

2. Key diagnostic question

Determine whether this is:
  1. Primary TR: structural leaflet/chordal abnormality
    • Infective endocarditis
    • Flail leaflet/trauma
    • Carcinoid disease
    • Rheumatic/congenital disease
    • Device lead-related TR
  2. Secondary (functional) TR, which is more common
    • RA/annular dilatation from atrial fibrillation
    • RV dilatation due to PH
    • Left-sided valve disease or LV dysfunction
    • RV cardiomyopathy/infarction
    • Pulmonary embolism or chronic thromboembolic PH
Secondary TR is commonly associated with pulmonary hypertension, left-sided heart/valve disease, RV disease, and atrial fibrillation. Fuster and Hurst's The Heart, 15th Edition, p. 997.

3. Urgent investigations

A. Echocardiography, preferably comprehensive TTE urgently

Assess:
  • TR mechanism: leaflet morphology, flail/prolapse, tethering, annular size, device lead interaction, vegetation
  • TR severity: vena contracta, PISA/EROA where feasible, hepatic-vein systolic flow reversal, regurgitant volume
  • RA/RV size and RV systolic function: TAPSE, S', FAC, RV strain if available
  • IVC size and inspiratory collapse, estimated RA pressure
  • RV pressure overload: septal flattening/D-shaped LV
  • LV ejection fraction, diastolic indices, LA size
  • Mitral/aortic valve disease
  • Pericardial effusion or tamponade physiology
  • Estimate PH probability, but recognize that a very severe TR jet may underestimate RV-PA gradient.
Proceed to transesophageal echo (TEE) if the mechanism remains unclear, endocarditis is suspected, imaging is inadequate, or intervention is being considered.

B. Exclude pulmonary embolism promptly

Acute dyspnea with right-heart enlargement requires active consideration of PE.
  • CTPA if clinically appropriate and renal function permits
  • V/Q scan if CTPA is contraindicated or if evaluating for chronic thromboembolic PH (CTEPH)
  • Lower-limb venous Doppler can support the diagnosis when pulmonary imaging is delayed or unsuitable
After echo evidence of PH, evaluation should include PFTs and V/Q scanning to assess lung disease, occult chronic thromboembolic disease, and sleep-disordered breathing. Fishman's Pulmonary Diseases and Disorders, section “Pulmonary Function Testing, Ventilation-Perfusion Scanning, Sleep Studies.”

C. Define and confirm pulmonary hypertension

Echo detects probability, but right-heart catheterization (RHC) confirms and classifies PH when its result will alter management, particularly when PAH or CTEPH is possible.
Obtain:
  • Mean pulmonary artery pressure (mPAP)
  • Pulmonary artery wedge pressure (PAWP)
  • Cardiac output/index
  • Pulmonary vascular resistance (PVR)
  • RA pressure, mixed venous oxygen saturation
Current hemodynamic definition:
  • PH: mPAP >20 mmHg
  • Precapillary PH/PAH physiology: mPAP >20, PAWP ≤15 mmHg, PVR >2 Wood units
The ESC/ERS pathway is suspicion, echo-based detection, and confirmation by RHC in an experienced PH center, as summarized in the ESC/ERS PH guideline.

D. Determine PH group before using PH-targeted drugs

  • Group 1 PAH: connective tissue disease, portal hypertension, HIV, drugs/toxins, congenital heart disease
  • Group 2: left-heart disease, HFpEF/HFrEF, mitral/aortic disease
  • Group 3: COPD, ILD, OSA/hypoventilation, chronic hypoxia
  • Group 4: CTEPH
  • Group 5: multifactorial causes
Suggested targeted work-up:
  • PFT with DLCO, ABG, overnight oximetry/sleep study
  • High-resolution CT chest if ILD suspected
  • V/Q scan for CTEPH
  • ANA, ENA, anticentromere, anti-Scl-70 if connective-tissue disease suspected
  • HIV, liver evaluation/portal-hypertension assessment where relevant
  • Coronary assessment if ischemia or intervention is contemplated
  • Cardiac MRI if RV cardiomyopathy, congenital shunt, infiltrative disease, or uncertain RV function is suspected

4. Acute treatment

A. Treat congestion without excessively reducing RV preload

If there is edema, ascites, raised JVP, hepatic congestion, or pulmonary congestion:
  • Use careful IV loop diuresis, with daily weight, fluid balance, BP, renal function, sodium, potassium, and magnesium monitoring.
  • Add sequential nephron blockade only with close monitoring if diuretic resistance occurs.
  • Restrict sodium. Fluid restriction is individualized, mainly for marked congestion/hyponatremia.
Diuresis can improve RV mechanics by reducing RV wall stress, TR, and interventricular septal shift. Medical therapy for severe symptomatic TR is mainly cautious diuretic therapy while treating the underlying cause. Fuster and Hurst's The Heart, 15th Edition, p. 997.
Avoid both extremes:
  • Excess IV fluid can worsen TR, septal shift, hepatic congestion, and cardiac output.
  • Overdiuresis can reduce RV preload and precipitate hypotension/low output.

B. If hypotension or acute RV failure

This needs ICU-level management:
  • Identify and reverse trigger: PE, sepsis, arrhythmia, hypoxia, acidosis, ischemia, tamponade
  • Avoid hypoxemia, hypercapnia, acidosis, and unnecessary high PEEP because each raises pulmonary vascular resistance
  • Vasopressor support is often required to preserve coronary perfusion pressure in shock, commonly norepinephrine in monitored care
  • Add inotrope support if low-output RV failure persists despite adequate perfusion pressure
  • Inhaled pulmonary vasodilators may be used as a short-term rescue in selected ICU patients under specialist supervision
  • Avoid intubation if possible; if unavoidable, use an experienced team because induction and positive-pressure ventilation can cause circulatory collapse in severe RV failure/PH

C. Specific etiologic therapy

  • Acute PE: anticoagulate unless contraindicated. If high-risk PE with shock, assess urgently for reperfusion therapy, catheter-directed treatment, or surgical embolectomy.
  • Endocarditis: obtain cultures, perform TEE, begin pathogen-directed IV antibiotics, and involve an endocarditis/valve team. Acute severe TR with uncontrolled infection, persistent bacteremia, recurrent septic emboli, or refractory right-heart failure may require surgery.
  • Atrial fibrillation/flutter: correct precipitant, optimize rate or rhythm strategy, and anticoagulate according to stroke-risk and bleeding assessment. AF can itself drive RA dilatation and “atrial functional” TR.
  • Left-heart disease/valve disease: guideline-directed treatment of HF, hypertension, ischemia, and mitral/aortic disease. Do not routinely give PAH-specific vasodilators for PH due to left-heart disease.
  • Lung disease/OSA/hypoxia: optimize lung therapy, treat sleep-disordered breathing, smoking cessation, and oxygen for documented chronic hypoxemia.
  • CTEPH: lifelong anticoagulation and referral to a CTEPH center for operability assessment, pulmonary endarterectomy, balloon pulmonary angioplasty, and/or specialist drug therapy.
  • Confirmed Group 1 PAH: refer to a PH center for risk-based combination PAH therapy. This should not be initiated simply from an echocardiographic “moderate PAH” estimate.

5. Definitive TR management

Refer early to a multidisciplinary valve center, especially if severe TR is symptomatic, there is progressive RA/RV enlargement, recurrent right-sided HF admissions, declining RV function, or inadequate response to decongestion.
Options:
  • Surgical tricuspid repair is generally preferred over replacement when feasible.
  • Surgery is particularly appropriate when the patient is already undergoing left-sided valve surgery and has severe TR.
  • Isolated surgery may be appropriate for symptomatic severe primary TR or selected severe secondary TR before end-stage RV failure, severe PH, or advanced hepatic/renal injury develops.
  • Transcatheter tricuspid edge-to-edge repair/replacement is an option for selected symptomatic patients at high surgical risk with suitable anatomy.
Recent meta-analyses of randomized transcatheter TR trials support symptomatic and TR-severity improvement, but patient selection and long-term hard-outcome benefit remain evolving. Relevant recent reviews include PMID 41145332 and PMID 40803660.

Practical plan for this presentation

  1. Admit urgently, monitor, oxygen only if hypoxemic, evaluate hemodynamics.
  2. Urgent expert echo plus ECG, CXR, BNP/troponin, renal/liver profile, ABG/lactate.
  3. Exclude PE and endocarditis based on clinical probability.
  4. Start carefully titrated IV diuresis if clinically congested.
  5. Avoid empiric PAH-specific therapy until RHC and PH-group classification.
  6. Obtain TEE if primary TR, endocarditis, or intervention is possible.
  7. Refer early to both a PH center and valve/interventional heart team.
This is a shared conversation. Sign in to Orris to start your own chat.